1. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Issue 2 (8th July 2009) Authors: Coombs, J H; Bloom, B J; Breedveld, F C; Fletcher, M P; Gruben, D; Kremer, J M; Burgos-Vargas, R; Wilkinson, B; Zerbini, C A F; Zwillich, S H Journal: Annals of the rheumatic diseases Issue: Volume 69:Issue 2(2010) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development. Issue 6 (14th March 2013) Authors: Milligan, P A; Brown, M J; Marchant, B; Martin, S W; van der Graaf, P H; Benson, N; Nucci, G; Nichols, D J; Boyd, R A; Mandema, J W; Krishnaswami, S; Zwillich, S; Gruben, D; Anziano, R J; Stock, T C; Lalonde, R L Journal: Clinical pharmacology & therapeutics Issue: Volume 93:Issue 6(2013) Page Start: 502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0022 TNFI and TOFACITINIB monotherapy and comparative effectiveness in clinical practice: results from corrona registry. (15th June 2017) Authors: Reed, GW; Gerber, RA; Shan, Y; Takiya, L; Dandreo, KJ; Gruben, D; Kremer, JM; Wallenstein, GV Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗